Targeted Combo Plus Chemo Improves Survival in BRAF-Mutated CRC

(MedPage Today) -- CHICAGO -- First-line treatment with encorafenib (Braftovi) and cetuximab (Erbitux) plus chemotherapy significantly improved survival outcomes compared with standard of care in patients with BRAF V600E-mutated metastatic colorectal...